Eyyüp Çavdar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eyyüp Çavdar has a total of 305 co-authors. Here are the top co-authors by number of shared publications:
- Kubilay Karaboyun
Division of Medical Oncology, Department of Internal Medicine, Tekirdağ Namık Kemal University, Tekirdağ 59030, Turkey
15 shared publications - Selcuk Seber
Tekirdag Namik Kemal University, Turkey
14 shared publications - Okan Avcı
Tekirdag Namik Kemal University, Turkey
12 shared publications - Yakup İrIagac
Balıkesir Atatürk Şehir Hastanesi
12 shared publications - Meltem Öznur
Tekirdag Namik Kemal University, Turkey
6 shared publications Yakup Iriagac
Balikesir Atatürk City Hospital, Turkey
6 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-14
Association Between Blood Transfusion and Survival Outcomes in Metastatic Cutaneous Melanoma Treated with Nivolumab
Objective: Immune checkpoint inhibitors (ICIs) are a cornerstone in the treatment of metastatic cutaneous malignant melanoma (cMM). Blood transfusions exert immunomodulatory effects that may impair antitumor immunity; however, their impact on survival outcomes in patients receiving ICIs remains unclear. This study evaluated the association between blood transfusion and survival outcomes in patients with metastatic cMM treated with nivolumab. Methods: In this retrospective cohort study, 57 patients with metastatic cMM who received nivolumab as second-line therapy between January 2018 and December 2023 were analyzed. Blood transfusion exposure during the metastatic stage and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were assessed. Results: The median age was 60.0 years (range, 25.0– 87.0). Median follow-up was 55.0 months. Median PFS was 10.23 months (95% confidence interval [CI], not estimable to 21.53), and median OS was 31.93 months (95% CI, not estimable to 66.31). Kaplan-Meier analysis demonstrated significantly worse PFS and OS among patients who received red blood cell (RBC) transfusions (Log Rank, p = 0.024, p = 0.016, respectively). In univariate Cox regression analysis, melanoma localization, brain metastases at metastatic onset, shorter nivolumab duration, and RBC transfusion exposure were associated with poorer survival outcomes. Conclusion: Blood transfusion during the metastatic stage was associated with reduced survival in patients with metastatic cMM receiving nivolumab. These findings suggest that transfusion-related immunomodulation may be associated with reduced immunotherapy efficacy and highlight RBC transfusion as a clinically relevant and potentially modifiable factor in patient management.
- 1 June 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-14
Open AccessAssociation Between Blood Transfusion and Survival Outcomes in Metastatic Cutaneous Melanoma Treated with Nivolumab
Objective: Immune checkpoint inhibitors (ICIs) are a cornerstone in the treatment of metastatic cutaneous malignant melanoma (cMM). Blood transfusions exert immunomodulatory effects that may impair antitumor immunity; however, their impact on survival outcomes in patients receiving ICIs remains unclear. This study evaluated the association between blood transfusion and survival outcomes in patients with metastatic cMM treated with nivolumab. Methods: In this retrospective cohort study, 57 patients with metastatic cMM who received nivolumab as second-line therapy between January 2018 and December 2023 were analyzed. Blood transfusion exposure during the metastatic stage and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were assessed. Results: The median age was 60.0 years (range, 25.0– 87.0). Median follow-up was 55.0 months. Median PFS was 10.23 months (95% confidence interval [CI], not estimable to 21.53), and median OS was 31.93 months (95% CI, not estimable to 66.31). Kaplan-Meier analysis demonstrated significantly worse PFS and OS among patients who received red blood cell (RBC) transfusions (Log Rank, p = 0.024, p = 0.016, respectively). In univariate Cox regression analysis, melanoma localization, brain metastases at metastatic onset, shorter nivolumab duration, and RBC transfusion exposure were associated with poorer survival outcomes. Conclusion: Blood transfusion during the metastatic stage was associated with reduced survival in patients with metastatic cMM receiving nivolumab. These findings suggest that transfusion-related immunomodulation may be associated with reduced immunotherapy efficacy and highlight RBC transfusion as a clinically relevant and potentially modifiable factor in patient management.
- Open Access
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
Background and Objectives: Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard of care for resectable gastric and gastroesophageal junction adenocarcinoma; however, up to 50% of patients develop metastatic recurrence. These patients have prior exposure to platinum and taxane agents, and optimal first-line treatment in the metastatic setting remains undefined. This study aimed to characterize real-world treatment patterns and outcomes in patients progressing after perioperative FLOT, focusing on relapse timing and HER2 status. Materials and Methods: This retrospective, multicenter cohort study included 296 patients from 31 centers across Türkiye, stratified into early relapse (≤6 months, n = 114) and late relapse (>6 months, n = 182) groups. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards regression. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median PFS and OS for the entire cohort were 6 and 9 months, respectively. Early relapsers had significantly shorter median PFS (4 vs. 6 months, p = 0.029) and OS (8 vs. 12 months, p = 0.047); however, early relapse timing did not retain independent prognostic significance on multivariable analysis. No significant difference in PFS or OS was observed between cytotoxic chemotherapy regimens in either relapse group. HER2 positivity was the only independent predictor of improved PFS on multivariable Cox analysis (HR 0.48, 95% CI 0.29–0.81; p = 0.006). In the late relapse group, trastuzumab-based chemotherapy achieved a median PFS of 14 months and OS of 18 months, significantly superior to all cytotoxic regimens (PFS p = 0.007; OS p = 0.029). Conclusions: In patients progressing after perioperative FLOT, cytotoxic chemotherapy regimen selection did not demonstrate a statistically significant survival difference in this retrospective cohort, regardless of relapse timing. HER2 positivity is the dominant predictive biomarker, and trastuzumab-based therapy suggests a potential survival benefit that warrants prospective validation. Comprehensive biomarker profiling at metastatic diagnosis and prospective trials designed for this post-FLOT population are needed to establish evidence-based treatment standards.
Open AccessFirst-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
Background and Objectives: Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard of care for resectable gastric and gastroesophageal junction adenocarcinoma; however, up to 50% of patients develop metastatic recurrence. These patients have prior exposure to platinum and taxane agents, and optimal first-line treatment in the metastatic setting remains undefined. This study aimed to characterize real-world treatment patterns and outcomes in patients progressing after perioperative FLOT, focusing on relapse timing and HER2 status. Materials and Methods: This retrospective, multicenter cohort study included 296 patients from 31 centers across Türkiye, stratified into early relapse (≤6 months, n = 114) and late relapse (>6 months, n = 182) groups. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards regression. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median PFS and OS for the entire cohort were 6 and 9 months, respectively. Early relapsers had significantly shorter median PFS (4 vs. 6 months, p = 0.029) and OS (8 vs. 12 months, p = 0.047); however, early relapse timing did not retain independent prognostic significance on multivariable analysis. No significant difference in PFS or OS was observed between cytotoxic chemotherapy regimens in either relapse group. HER2 positivity was the only independent predictor of improved PFS on multivariable Cox analysis (HR 0.48, 95% CI 0.29–0.81; p = 0.006). In the late relapse group, trastuzumab-based chemotherapy achieved a median PFS of 14 months and OS of 18 months, significantly superior to all cytotoxic regimens (PFS p = 0.007; OS p = 0.029). Conclusions: In patients progressing after perioperative FLOT, cytotoxic chemotherapy regimen selection did not demonstrate a statistically significant survival difference in this retrospective cohort, regardless of relapse timing. HER2 positivity is the dominant predictive biomarker, and trastuzumab-based therapy suggests a potential survival benefit that warrants prospective validation. Comprehensive biomarker profiling at metastatic diagnosis and prospective trials designed for this post-FLOT population are needed to establish evidence-based treatment standards.
- Open Access
- 25 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Predictive role of vulnerable elderly study-13 screening tools in chemotherapy-related toxicity in elderly patients with lung cancer
Lung cancer patients are frail because they are usually diagnosed at an advanced age, are often accompanied by comorbidities, and are at high risk of chemotherapy toxicity. Choosing a safe and correct treatment is very important. In this study, we investigated the ability of VES-13, which measures patient frailty, to predict the side effects of chemotherapeutic drugs. This was a prospective, single-center observational study in which 131 patients aged ≥ 65 years who were scheduled to receive chemotherapy due to a lung cancer diagnosis were included. The VES-13 questionnaire was completed by all patients before treatment. Treatment-related toxicities (TRTs) while receiving chemotherapy treatment were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. The median age was 70 (65–85) years. There was hematologic toxicity in 46 (35.1%) patients and nonhematologic grade 3–5 toxicity in 33 (25.2%) patients. In the univariate analysis, VES-13 (OR = 8.40, p < 0.001), platinum chemotherapy (OR = 2.53, p = 0.016) and ECOG-PS (OR = 2.60, p = 0.018) were found to be predictive of TRT. In the multivariate analysis, VES-13 remained an independent predictive feature when the predictors were evaluated together (OR = 8.26, p < 0.001). The detection of abnormal scores with the VES-13 tool revealed a greater need for initial treatment dose reduction, treatment interruption, treatment discontinuation, blood transfusion and unexpected hospital admission (p = 0.012, p < 0.001, p < 0.001, p = 0.022, and p < 0.001, respectively). We believe that the VES-13 questionnaire is a useful tool for deciding on a chemotherapy and choosing the appropriate regimen and that it should be used in outpatient clinic conditions because it is easy and short to apply.
- 25 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPredictive role of vulnerable elderly study-13 screening tools in chemotherapy-related toxicity in elderly patients with lung cancer
Lung cancer patients are frail because they are usually diagnosed at an advanced age, are often accompanied by comorbidities, and are at high risk of chemotherapy toxicity. Choosing a safe and correct treatment is very important. In this study, we investigated the ability of VES-13, which measures patient frailty, to predict the side effects of chemotherapeutic drugs. This was a prospective, single-center observational study in which 131 patients aged ≥ 65 years who were scheduled to receive chemotherapy due to a lung cancer diagnosis were included. The VES-13 questionnaire was completed by all patients before treatment. Treatment-related toxicities (TRTs) while receiving chemotherapy treatment were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. The median age was 70 (65–85) years. There was hematologic toxicity in 46 (35.1%) patients and nonhematologic grade 3–5 toxicity in 33 (25.2%) patients. In the univariate analysis, VES-13 (OR = 8.40, p < 0.001), platinum chemotherapy (OR = 2.53, p = 0.016) and ECOG-PS (OR = 2.60, p = 0.018) were found to be predictive of TRT. In the multivariate analysis, VES-13 remained an independent predictive feature when the predictors were evaluated together (OR = 8.26, p < 0.001). The detection of abnormal scores with the VES-13 tool revealed a greater need for initial treatment dose reduction, treatment interruption, treatment discontinuation, blood transfusion and unexpected hospital admission (p = 0.012, p < 0.001, p < 0.001, p = 0.022, and p < 0.001, respectively). We believe that the VES-13 questionnaire is a useful tool for deciding on a chemotherapy and choosing the appropriate regimen and that it should be used in outpatient clinic conditions because it is easy and short to apply.
- 19 February 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (4) , 1621-1629
Beyond the Patient: The Association Between Patient Functional Disability, Caregiver Burden, and Mental Health in Oncology
- 19 February 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (4) , 1621-1629
Beyond the Patient: The Association Between Patient Functional Disability, Caregiver Burden, and Mental Health in Oncology
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (5) , e20252145
Independent prognostic ımpact of perineural ınvasion in breast cancer patients with residual disease after neoadjuvant chemotherapy
SUMMARY OBJECTIVE: Perineural invasion is a well-established adverse prognostic factor in several malignancies, yet its prognostic role in breast cancer remains controversial. METHODS: We retrospectively analyzed 400 breast cancer patients treated with neoadjuvant chemotherapy between 2012 and 2025 who had residual disease (non-pCR) at surgery. Clinicopathological variables, recurrence-free survival, and overall survival were evaluated using Cox proportional hazards models. RESULTS: Perineural invasion was identified in 42.5% of the cohort and associated with larger tumor burden, lymphovascular invasion, and nodal metastasis (p<0.01). Perineural invasion-positive status correlated with significantly inferior median recurrence-free survival (100.5 vs. 120.4 months; HR 1.77, p=0.008) and overall survival (108.5 vs. 133.6 months; HR 3.11, p<0.001). Multivariate analysis confirmed perineural invasion as a robust independent predictor of shorter recurrence-free survival and overall survival. The adverse impact was evident across all molecular subtypes, particularly HR+/HER2- and HER2+ groups. CONCLUSION: Perineural invasion is a strong independent prognostic factor for recurrence-free survival and overall survival in breast cancer patients with residual disease after neoadjuvant chemotherapy. Reporting perineural invasion status in routine pathology evaluations may aid in risk stratification for this high-risk population.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (5) , e20252145
Open AccessIndependent prognostic ımpact of perineural ınvasion in breast cancer patients with residual disease after neoadjuvant chemotherapy
SUMMARY OBJECTIVE: Perineural invasion is a well-established adverse prognostic factor in several malignancies, yet its prognostic role in breast cancer remains controversial. METHODS: We retrospectively analyzed 400 breast cancer patients treated with neoadjuvant chemotherapy between 2012 and 2025 who had residual disease (non-pCR) at surgery. Clinicopathological variables, recurrence-free survival, and overall survival were evaluated using Cox proportional hazards models. RESULTS: Perineural invasion was identified in 42.5% of the cohort and associated with larger tumor burden, lymphovascular invasion, and nodal metastasis (p<0.01). Perineural invasion-positive status correlated with significantly inferior median recurrence-free survival (100.5 vs. 120.4 months; HR 1.77, p=0.008) and overall survival (108.5 vs. 133.6 months; HR 3.11, p<0.001). Multivariate analysis confirmed perineural invasion as a robust independent predictor of shorter recurrence-free survival and overall survival. The adverse impact was evident across all molecular subtypes, particularly HR+/HER2- and HER2+ groups. CONCLUSION: Perineural invasion is a strong independent prognostic factor for recurrence-free survival and overall survival in breast cancer patients with residual disease after neoadjuvant chemotherapy. Reporting perineural invasion status in routine pathology evaluations may aid in risk stratification for this high-risk population.
- Open Access
- 17 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (20) , 2612
Attachment Styles as Protective and Amplifying Factors in Caregiver Psychological Distress: A Multicenter Cross-Sectional Study in Oncology and Chronic Disease Caregiving
Background/Objectives: Caregiving for patients with advanced cancer or chronic illness imposes substantial psychological burden, yet the role of caregiver attachment style in moderating this distress is underexplored. This multicenter, cross-sectional study investigates how attachment styles influence the relationship between psychological distress and caregiver burden in two populations: family caregivers of palliative-stage cancer patients and those supporting patients with chronic diseases. Methods: Across Turkey, 819 caregivers (412 cancer, 407 chronic disease) completed the Zarit Caregiver Burden Scale, DASS-21, and Relationship Scale Questionnaire. Hayes’ PROCESS macro was used to test the moderating role of attachment styles. Results: Cancer caregivers reported higher caregiver burden (Cohen’s d = 0.35, 95% CI [0.21, 0.49]) and stress than chronic disease caregivers, but lower depression. Secure attachment was negatively associated with burden, while preoccupied attachment was positively associated. For cancer caregivers, secure attachment buffered the impact of depression on burden (interaction B = –0.611, 95% CI [–0.861, –0.361]), whereas preoccupied attachment amplified it in both groups (cancer caregivers: B = 0.292, 95% CI [0.064, 0.520]; chronic disease caregivers B = 0.505, 95% CI [0.174, 0.836]). The final regression models explained 43.1% of variance in burden for the cancer group and 10.9% for the chronic disease group. Conclusions: Attachment styles are significant moderators of the relationship between psychological distress and caregiver burden. Secure attachment is a protective factor, while preoccupied attachment is a vulnerability factor. These findings underscore the need for attachment-informed psychosocial interventions tailored to specific caregiver profiles to mitigate distress.
- 17 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (20) , 2612
Open AccessAttachment Styles as Protective and Amplifying Factors in Caregiver Psychological Distress: A Multicenter Cross-Sectional Study in Oncology and Chronic Disease Caregiving
Background/Objectives: Caregiving for patients with advanced cancer or chronic illness imposes substantial psychological burden, yet the role of caregiver attachment style in moderating this distress is underexplored. This multicenter, cross-sectional study investigates how attachment styles influence the relationship between psychological distress and caregiver burden in two populations: family caregivers of palliative-stage cancer patients and those supporting patients with chronic diseases. Methods: Across Turkey, 819 caregivers (412 cancer, 407 chronic disease) completed the Zarit Caregiver Burden Scale, DASS-21, and Relationship Scale Questionnaire. Hayes’ PROCESS macro was used to test the moderating role of attachment styles. Results: Cancer caregivers reported higher caregiver burden (Cohen’s d = 0.35, 95% CI [0.21, 0.49]) and stress than chronic disease caregivers, but lower depression. Secure attachment was negatively associated with burden, while preoccupied attachment was positively associated. For cancer caregivers, secure attachment buffered the impact of depression on burden (interaction B = –0.611, 95% CI [–0.861, –0.361]), whereas preoccupied attachment amplified it in both groups (cancer caregivers: B = 0.292, 95% CI [0.064, 0.520]; chronic disease caregivers B = 0.505, 95% CI [0.174, 0.836]). The final regression models explained 43.1% of variance in burden for the cancer group and 10.9% for the chronic disease group. Conclusions: Attachment styles are significant moderators of the relationship between psychological distress and caregiver burden. Secure attachment is a protective factor, while preoccupied attachment is a vulnerability factor. These findings underscore the need for attachment-informed psychosocial interventions tailored to specific caregiver profiles to mitigate distress.
- Open Access
- 26 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (39) , e44743
The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer
Background: The prognostic and predictive role of the interaction of the immune system with the tumor during the disease process has become increasingly important in recent years. T lymphocyte subgroups in peripheral blood can be used to monitor this dynamic interaction. We evaluated the relationship between baseline peripheral T lymphocyte subsets and treatment response (best objective response) in 47 breast cancer patients receiving neoadjuvant chemotherapy. Methods: This study investigated the impact of initial peripheral T lymphocyte subsets on neoadjuvant chemotherapy response in patients with invasive ductal breast. A total of 47 consecutive patients whose peripheral blood samples were able was included in the study group. The patients’ T lymphocyte subsets were measured before treatment. The patients were then followed up to assess their treatment response. Results: In our study, we found a significant negative relationship between baseline CD3, CD4, and CD8 absolute counts and pathologic complete response. We also found that high CD4/programmed cell death protein 1 expression (OR: 0.212, 95% CI: 0.061–0.735, P = .015) and high CD8/programmed cell death protein 1 expression (OR: 0.250, 95% CI: 0.073–0.858, P = .028) from baseline peripheral T lymphocyte were correlated with poor pathologic complete response. Conclusions: These results suggest that T lymphocyte subsets may be a predictive biomarker for treatment response in patients with breast cancer undergoing neoadjuvant chemotherapy. Further studies are needed to confirm these findings and to identify the optimal T lymphocyte subset for predicting treatment response.
- 26 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (39) , e44743
Open AccessThe role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer
Background: The prognostic and predictive role of the interaction of the immune system with the tumor during the disease process has become increasingly important in recent years. T lymphocyte subgroups in peripheral blood can be used to monitor this dynamic interaction. We evaluated the relationship between baseline peripheral T lymphocyte subsets and treatment response (best objective response) in 47 breast cancer patients receiving neoadjuvant chemotherapy. Methods: This study investigated the impact of initial peripheral T lymphocyte subsets on neoadjuvant chemotherapy response in patients with invasive ductal breast. A total of 47 consecutive patients whose peripheral blood samples were able was included in the study group. The patients’ T lymphocyte subsets were measured before treatment. The patients were then followed up to assess their treatment response. Results: In our study, we found a significant negative relationship between baseline CD3, CD4, and CD8 absolute counts and pathologic complete response. We also found that high CD4/programmed cell death protein 1 expression (OR: 0.212, 95% CI: 0.061–0.735, P = .015) and high CD8/programmed cell death protein 1 expression (OR: 0.250, 95% CI: 0.073–0.858, P = .028) from baseline peripheral T lymphocyte were correlated with poor pathologic complete response. Conclusions: These results suggest that T lymphocyte subsets may be a predictive biomarker for treatment response in patients with breast cancer undergoing neoadjuvant chemotherapy. Further studies are needed to confirm these findings and to identify the optimal T lymphocyte subset for predicting treatment response.
- 7 August 2025
- Published by Academician Publishing
- p. 675-686
Kanser Hastalarında Bilişsel İşlev Bozukluğu
Kanser hastalarında hem tedavi sırasında hem de tedavi sonrası remisyon takibinde bilişsel değişiklikler ve bozukluklar meydana gelebilir. Bu, kanserin, komorbid durumların ve uygulanan tedavilerin doğrudan veya dolaylı etkisiyle ilişkili olabilir. Dikkat, bellek ve yönetici işlevler, kanserden etkilenen en sık tanımlanan bilişsel alanlardır. Etkili bir takip ve tanı süreci erken müdahale fırsatlarını artırırken, bireyselleştirilmiş tedavi yaklaşımlarıyla yönetim stratejileri geliştirmek mümkündür. Ancak henüz altın standart bir tanı ve takip yöntemi yoktur. Nöropsikolojik testler (MoCA MMSE gibi), laboratuvar analizleri ve görüntüleme yöntemleri (MRI gibi) yardımcı olabilir. Bu yöntemlerin bir kombinasyonu ile düzenli takip yapılır, hastaların bireysel ihtiyaçlarına uygun stratejilerin geliştirilmesine ve yaşam kalitesinin artmasına olanak tanır. Cognitive changes and impairments may occur in cancer patients both during treatment and post-treatment remission follow-up. This may be related to the direct or indirect effect of cancer, comorbid conditions, and applied treatments. Attention, memory, and executive functions are the most frequently identified cognitive areas affected by cancer. While an effective follow-up and diagnosis process increases early intervention opportunities, it is possible to develop management strategies with individualized treatment approaches. However, there is no gold standard diagnosis and follow-up method yet. Neuropsychological tests (such as MoCA MMSE), laboratory analyses, and imaging methods (such as MRI) can be helpful. Regular follow-up is performed with a combination of these methods, allowing the development of strategies appropriate to the individual needs of patients and the increase in quality of life.
- 7 August 2025
- Published by Academician Publishing
- p. 675-686
Kanser Hastalarında Bilişsel İşlev Bozukluğu
Kanser hastalarında hem tedavi sırasında hem de tedavi sonrası remisyon takibinde bilişsel değişiklikler ve bozukluklar meydana gelebilir. Bu, kanserin, komorbid durumların ve uygulanan tedavilerin doğrudan veya dolaylı etkisiyle ilişkili olabilir. Dikkat, bellek ve yönetici işlevler, kanserden etkilenen en sık tanımlanan bilişsel alanlardır. Etkili bir takip ve tanı süreci erken müdahale fırsatlarını artırırken, bireyselleştirilmiş tedavi yaklaşımlarıyla yönetim stratejileri geliştirmek mümkündür. Ancak henüz altın standart bir tanı ve takip yöntemi yoktur. Nöropsikolojik testler (MoCA MMSE gibi), laboratuvar analizleri ve görüntüleme yöntemleri (MRI gibi) yardımcı olabilir. Bu yöntemlerin bir kombinasyonu ile düzenli takip yapılır, hastaların bireysel ihtiyaçlarına uygun stratejilerin geliştirilmesine ve yaşam kalitesinin artmasına olanak tanır. Cognitive changes and impairments may occur in cancer patients both during treatment and post-treatment remission follow-up. This may be related to the direct or indirect effect of cancer, comorbid conditions, and applied treatments. Attention, memory, and executive functions are the most frequently identified cognitive areas affected by cancer. While an effective follow-up and diagnosis process increases early intervention opportunities, it is possible to develop management strategies with individualized treatment approaches. However, there is no gold standard diagnosis and follow-up method yet. Neuropsychological tests (such as MoCA MMSE), laboratory analyses, and imaging methods (such as MRI) can be helpful. Regular follow-up is performed with a combination of these methods, allowing the development of strategies appropriate to the individual needs of patients and the increase in quality of life.
- Open Access
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations
Background and Objectives: Despite advances in immunotherapy, predicting survival outcomes in patients with non-small-cell lung cancer (NSCLC) remains challenging. Inflammatory and nutritional indices such as the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Inflammatory Burden Index (IBI) have emerged as promising prognostic markers associated with overall survival (OS) in NSCLC patients. Materials and Methods: We retrospectively analyzed a total of 196 NSCLC patients treated with second-line nivolumab across multiple centers in Turkey. Of these, 101 patients aged ≥ 65 years were included in the elderly subgroup analysis. PNI, GNRI (in patients aged ≥ 65), and inflammation-based indices were calculated using pre-treatment laboratory values. ROC analysis determined optimal cut-off values. The Kaplan–Meier method and Cox proportional hazards models were used for survival analysis. Results: Median overall survival (OS) was 12.9 months in the full cohort and 12.1 months in patients aged ≥ 65. In univariate analysis, ECOG performance status (0–1), lower NLR (p = 0.02] and elderly patients [HR: 0.45, 95% CI: 0.24–0.84; p = 0.01]. PNI is an independent prognostic biomarker for OS in NSCLC patients treated with immune checkpoint inhibitors. Conclusions: These findings support incorporating simple, cost-effective nutritional indices into clinical decision-making, particularly in elderly patients with NSCLC.
Open AccessPrognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations
Background and Objectives: Despite advances in immunotherapy, predicting survival outcomes in patients with non-small-cell lung cancer (NSCLC) remains challenging. Inflammatory and nutritional indices such as the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Inflammatory Burden Index (IBI) have emerged as promising prognostic markers associated with overall survival (OS) in NSCLC patients. Materials and Methods: We retrospectively analyzed a total of 196 NSCLC patients treated with second-line nivolumab across multiple centers in Turkey. Of these, 101 patients aged ≥ 65 years were included in the elderly subgroup analysis. PNI, GNRI (in patients aged ≥ 65), and inflammation-based indices were calculated using pre-treatment laboratory values. ROC analysis determined optimal cut-off values. The Kaplan–Meier method and Cox proportional hazards models were used for survival analysis. Results: Median overall survival (OS) was 12.9 months in the full cohort and 12.1 months in patients aged ≥ 65. In univariate analysis, ECOG performance status (0–1), lower NLR (p = 0.02] and elderly patients [HR: 0.45, 95% CI: 0.24–0.84; p = 0.01]. PNI is an independent prognostic biomarker for OS in NSCLC patients treated with immune checkpoint inhibitors. Conclusions: These findings support incorporating simple, cost-effective nutritional indices into clinical decision-making, particularly in elderly patients with NSCLC.